Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients

Michikata Hayashida, Aya Nishida, Mika Kuno, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Suguru Oka, Kazushige Sakaguchi, Shinji Urakami, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2024-199936

Published: 2024

Journal Articles

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

Shunsuke Nishino, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2024-205008

Published: 2024

Journal Articles

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Yuki Taya, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 7437.

https://doi.org/10.1182/blood-2024-208778

Published: 2024

Journal Articles

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Jotaro Yamamoto, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2024-201930

Published: 2024

Journal Articles

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Ryo Koizumi, Shinsuke Takagi, Aya Nishida, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Kazuya Ishiwata, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2024-203327

Published: 2024

Journal Articles

Transformative Outcomes with Short-Term Blinatumomab and Cord Blood Transplantation in Relapsed/Refractory B-Cell ALL

Aya Nishida, Mika Kuno, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 7304.

https://doi.org/10.1182/blood-2024-198310

Published: 2024

Journal Articles

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2024-210383

Published: 2024

Journal Articles

Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis

Shotaro Shimada, Naoyuki Uchida, Hisashi Yamamoto, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Yuki Asano-Mori, Go Yamamoto

Blood (2024) 144 (Supplement 1): 4926.

https://doi.org/10.1182/blood-2024-207383

Published: 2024

Journal Articles

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4920.

https://doi.org/10.1182/blood-2024-198879

Published: 2024

Journal Articles

Excellent Outcome Following Maintenance Therapy with Gilteritinib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia Even in Non-Remission Status

Aya Nishida, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 4989.

https://doi.org/10.1182/blood-2023-182632

Published: 2023

Journal Articles

Comparison of Myeloablative Conditioning with Cyclophosphamide and Total-Body Irradiation (Cy/TBI) Vs. Fludarabine, Melphalan, and Total-Body Irradiation (Flu/Mel/TBI) in Patients Undergoing Allogeneic Stem Cell Transplant for AML/ALL

Tomoyo Kubo, Hisashi Yamamoto, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 4917.

https://doi.org/10.1182/blood-2023-182732

Published: 2023

Journal Articles

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Kazuya Ishiwata, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2023) 142 (Supplement 1): 6931.

https://doi.org/10.1182/blood-2023-184637

Published: 2023

Journal Articles

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapse or Refractory Peripheral T-Cell Lymphoma at Toranomon Hospital and Toranomon Hospital Kajigaya

Futoshi Yoshino, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2023) 142 (Supplement 1): 6191.

https://doi.org/10.1182/blood-2023-185447

Published: 2023

Journal Articles

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2023-188946

Published: 2023

Journal Articles

Pre-Engraftment Immune Reactions Has Unique Graft-Versus-Leukemia Effects after Single Cord Blood Transplantation

Yamamoto Hisashi, MD PhD, Naoyuki Uchida, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Takashi Mitsuki, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Shinsuke Takagi, Yuki Asano-Mori, MD PhD, Go Yamamoto, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 2041.

https://doi.org/10.1182/blood-2019-130550

Published: 2019

Journal Articles

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Shinsuke Takagi, Takashi Mitsuki, MD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD PhD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 5382.

https://doi.org/10.1182/blood-2019-129859

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Overcomes Negative Impact on Relapse Rate and Progression Free Survival in 294 Non-Remission AML Patients with Adverse Cytogenetic Abnormalities Other Than Monosomal or Complex Karyotype

Mitsuhiro Yuasa, MD, Michiho Ebihara, MD, Daisuke Kaji, MD, Kosei Kageyama, MD, Aya Nishida, MD, Shinsuke Takagi, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2018) 132 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2018-99-116212

Published: 2018

Journal Articles

High-Dose Intravenous Immunoglobulin and Immunosuppressive Therapy Have Therapeutic Potential for Non-Infectious Myelopathy and Peripheral Neuropathy Following Cord Blood Transplantation

Michiho Ebihara, MD, Shinsuke Takagi, Yoshikazu Uesaka, MD PhD, Takashi Mitsuki, MD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Yukako Koike, MD PhD, Shigeyoshi Makino, MD PhD, Akiko Yoneyama, MD PhD, Atsushi Wake, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2018) 132 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2018-99-116308

Published: 2018

Journal Articles

Cord Blood Units Containing Lower CD34 + Cells (0.5 - 1.0 x 10 5 /kg) Could be Alternative Donor Candidates for Single-Unit Cord Blood Transplantation for Adults: A Retrospective Study of 421 Patients in a Single Institute

Shinsuke Takagi, Mitsuhiro Yuasa, MD, Naoyuki Uchida, MD PhD, Michiho Ebihara, MD, Takashi Mitsuki, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Yukako Koike, MD PhD, Shigeyoshi Makino, MD PhD, Akiko Yoneyama, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2018) 132 (Supplement 1): 2089.

https://doi.org/10.1182/blood-2018-99-119827

Published: 2018

Journal Articles

Prospective Study of High Dose Foscarnet Prophylaxis for HHV-6 Related CNS Diseases in Cord Blood Transplantation for Adult Patients

Kazuya Ishiwata, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Aya Nishida, MD, Daisuke Kaji, MD, Shinsuke Takagi, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2017) 130 (Supplement 1): 3223.

https://doi.org/10.1182/blood.V130.Suppl_1.3223.3223

Published: 2017

NARROW

Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Transformative Outcomes with Short-Term Blinatumomab and Cord Blood Transplantation in Relapsed/Refractory B-Cell ALL

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Excellent Outcome Following Maintenance Therapy with Gilteritinib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia Even in Non-Remission Status

Comparison of Myeloablative Conditioning with Cyclophosphamide and Total-Body Irradiation (Cy/TBI) Vs. Fludarabine, Melphalan, and Total-Body Irradiation (Flu/Mel/TBI) in Patients Undergoing Allogeneic Stem Cell Transplant for AML/ALL

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapse or Refractory Peripheral T-Cell Lymphoma at Toranomon Hospital and Toranomon Hospital Kajigaya

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Pre-Engraftment Immune Reactions Has Unique Graft-Versus-Leukemia Effects after Single Cord Blood Transplantation

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Allogeneic Stem Cell Transplantation Overcomes Negative Impact on Relapse Rate and Progression Free Survival in 294 Non-Remission AML Patients with Adverse Cytogenetic Abnormalities Other Than Monosomal or Complex Karyotype

High-Dose Intravenous Immunoglobulin and Immunosuppressive Therapy Have Therapeutic Potential for Non-Infectious Myelopathy and Peripheral Neuropathy Following Cord Blood Transplantation

Cord Blood Units Containing Lower CD34 + Cells (0.5 - 1.0 x 10 5 /kg) Could be Alternative Donor Candidates for Single-Unit Cord Blood Transplantation for Adults: A Retrospective Study of 421 Patients in a Single Institute

Prospective Study of High Dose Foscarnet Prophylaxis for HHV-6 Related CNS Diseases in Cord Blood Transplantation for Adult Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only